announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...

A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...